CAR T-cell therapy
Coverage of CAR T-cell therapy in the Nexus archive.
- Man who beat rare cancer celebrates by canoeing 2,000 miles with his dog
Frank Carter, a 67-year-old cancer survivor from Orange County, Florida, completed a 2,000-mile canoe journey down the Missouri River with his dog, Amos, after overcoming mantle cell lymphoma through immunotherapy. The expedition, which took 64 days and faced extreme weather, followed his cancer treatment at Moffitt Cancer Center.
- Lupus patients in England in remission after pioneering NHS trial of GM therapy
Five lupus patients in England are in remission after participating in an NHS trial of CAR T-cell therapy, which genetically modifies their T-cells to target and destroy the disease. Doctors describe this as a medical breakthrough that could offer a cure for chronic autoimmune diseases.
- A single protein may be holding back CAR T cancer therapy
A newly identified protein called NFIL3 is found to cause CAR T-cell therapy to lose effectiveness over time by inducing exhaustion in engineered immune cells. Disabling NFIL3 in animal models improved the cells' strength and tumor control.
- 3D-printed lymph nodes could widen access to CAR T-cell therapy
CAR T-cell therapy, an effective cancer treatment, is limited by high costs and inaccessibility in many regions. A new method using 3D-printed lymph nodes could reduce production costs and improve global access.